Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: WTDEC who wrote (7157)	4/3/1998 8:46:00 AM
From: Jim Oravetz	Respond to of 8116

Here are some comments by Bagalay out of yesterdays WSJ($) Cytogen, Princeton, N.J., said Arthur Andersen examined its financial statements for 1995, 1996 and 1997 and concluded that "the company will require additional funding to continue operations which raise substantial doubt about its ability to continue as a going concern." John Bagalay, Cytogen's chief executive officer, said: "This is not an imminent problem. There's ample money for funding the company for the rest of the year." Cytogen also said that any projected cash shortfalls could be managed by deferring or eliminating some expenses during the year. In Nasdaq Stock Market trading, Cytogen shares fell 18.75 cents, or 8.7%, to $1.97.